VEGFA and non-small cell lung carcinoma: Bevacizumab (Bev), a human vascular endothelial growth factor (VEGF) inhibitor, has been studied and is approved for multiple tumor types, including non-small-cell lung cancer, colorectal cancer, renal cancer, genitourinary cancers, and recurrent glioblastoma.